KR102337598B1 - 암 치료 방법 - Google Patents

암 치료 방법 Download PDF

Info

Publication number
KR102337598B1
KR102337598B1 KR1020157033947A KR20157033947A KR102337598B1 KR 102337598 B1 KR102337598 B1 KR 102337598B1 KR 1020157033947 A KR1020157033947 A KR 1020157033947A KR 20157033947 A KR20157033947 A KR 20157033947A KR 102337598 B1 KR102337598 B1 KR 102337598B1
Authority
KR
South Korea
Prior art keywords
delete delete
entinostat
administration
cancer
embodiment provides
Prior art date
Application number
KR1020157033947A
Other languages
English (en)
Korean (ko)
Other versions
KR20160003182A (ko
Inventor
로버트 굿나우
피터 오덴트리치
Original Assignee
신닥스 파마슈티컬스, 인크.
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by 신닥스 파마슈티컬스, 인크. filed Critical 신닥스 파마슈티컬스, 인크.
Publication of KR20160003182A publication Critical patent/KR20160003182A/ko
Application granted granted Critical
Publication of KR102337598B1 publication Critical patent/KR102337598B1/ko

Links

Images

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
    • A61K31/44—Non condensed pyridines; Hydrogenated derivatives thereof
    • A61K31/4406—Non condensed pyridines; Hydrogenated derivatives thereof only substituted in position 3, e.g. zimeldine
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
    • A61K31/505—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim
    • A61K31/517—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim ortho- or peri-condensed with carbocyclic ring systems, e.g. quinazoline, perimidine
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/56—Compounds containing cyclopenta[a]hydrophenanthrene ring systems; Derivatives thereof, e.g. steroids
    • A61K31/565—Compounds containing cyclopenta[a]hydrophenanthrene ring systems; Derivatives thereof, e.g. steroids not substituted in position 17 beta by a carbon atom, e.g. estrane, estradiol
    • A61K31/568—Compounds containing cyclopenta[a]hydrophenanthrene ring systems; Derivatives thereof, e.g. steroids not substituted in position 17 beta by a carbon atom, e.g. estrane, estradiol substituted in positions 10 and 13 by a chain having at least one carbon atom, e.g. androstanes, e.g. testosterone
    • A61K31/5685—Compounds containing cyclopenta[a]hydrophenanthrene ring systems; Derivatives thereof, e.g. steroids not substituted in position 17 beta by a carbon atom, e.g. estrane, estradiol substituted in positions 10 and 13 by a chain having at least one carbon atom, e.g. androstanes, e.g. testosterone having an oxo group in position 17, e.g. androsterone
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/30—Macromolecular organic or inorganic compounds, e.g. inorganic polyphosphates
    • A61K47/36—Polysaccharides; Derivatives thereof, e.g. gums, starch, alginate, dextrin, hyaluronic acid, chitosan, inulin, agar or pectin
    • A61K47/38—Cellulose; Derivatives thereof
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/20—Pills, tablets, discs, rods
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/48—Preparations in capsules, e.g. of gelatin, of chocolate
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P11/00—Drugs for disorders of the respiratory system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P15/00—Drugs for genital or sexual disorders; Contraceptives
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P5/00—Drugs for disorders of the endocrine system
    • A61P5/24—Drugs for disorders of the endocrine system of the sex hormones
    • A61P5/32—Antioestrogens
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K2300/00—Mixtures or combinations of active ingredients, wherein at least one active ingredient is fully defined in groups A61K31/00 - A61K41/00

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • Medicinal Chemistry (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • General Health & Medical Sciences (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Organic Chemistry (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Epidemiology (AREA)
  • Endocrinology (AREA)
  • Reproductive Health (AREA)
  • Pulmonology (AREA)
  • Diabetes (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Inorganic Chemistry (AREA)
  • Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
KR1020157033947A 2013-05-03 2014-05-02 암 치료 방법 KR102337598B1 (ko)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
US201361819505P 2013-05-03 2013-05-03
US61/819,505 2013-05-03
PCT/US2014/036651 WO2014179738A1 (en) 2013-05-03 2014-05-02 Methods for the treatment of cancer

Publications (2)

Publication Number Publication Date
KR20160003182A KR20160003182A (ko) 2016-01-08
KR102337598B1 true KR102337598B1 (ko) 2021-12-10

Family

ID=51843995

Family Applications (1)

Application Number Title Priority Date Filing Date
KR1020157033947A KR102337598B1 (ko) 2013-05-03 2014-05-02 암 치료 방법

Country Status (6)

Country Link
EP (1) EP2991650A4 (ja)
JP (2) JP2016522188A (ja)
KR (1) KR102337598B1 (ja)
CN (1) CN105492007A (ja)
HK (1) HK1223547A1 (ja)
WO (1) WO2014179738A1 (ja)

Families Citing this family (4)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO2017004092A1 (en) * 2015-06-29 2017-01-05 Syndax Pharmaceuticals, Inc. Combination of hdac inhibitor and anti-pd-l1 antibody for treatment of cancer
JP2019524748A (ja) * 2016-07-20 2019-09-05 エーザイ・アール・アンド・ディー・マネジメント株式会社 がんの治療におけるエリブリン及びヒストンデアセチラーゼ阻害剤の使用
WO2018213665A1 (en) * 2017-05-19 2018-11-22 Syndax Pharmaceuticals, Inc. Combination therapies
MA52778A (fr) * 2018-06-06 2021-04-21 Arena Pharm Inc Méthodes de traitement de troubles associés au récepteur s1p1

Citations (1)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO2013033656A1 (en) * 2011-09-02 2013-03-07 Syndax Pharmaceuticals, Inc. Methods for the treatment of breast cancer

Family Cites Families (5)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
CN101175492B (zh) * 2005-03-11 2013-10-16 科罗拉多大学董事会 组蛋白脱乙酰酶抑制剂使癌细胞对表皮生长因子抑制剂敏感
EP2046299A1 (en) * 2006-07-11 2009-04-15 Mutual Pharmaceutical Company, Inc. Controlled-release formulations
WO2009067500A1 (en) * 2007-11-19 2009-05-28 Syndax Pharmaceuticals, Inc. Administration of an inhibitor of hdac
WO2009109844A1 (en) * 2008-03-07 2009-09-11 Pfizer Inc. Methods, dosage forms, and kits for administering ziprasidone without food
WO2009126662A1 (en) * 2008-04-08 2009-10-15 Syndax Pharmaceuticals, Inc. Administration of an inhibitor of hdac, an inhibitor of her-2, and a selective estrogen receptor modulator

Patent Citations (1)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO2013033656A1 (en) * 2011-09-02 2013-03-07 Syndax Pharmaceuticals, Inc. Methods for the treatment of breast cancer

Also Published As

Publication number Publication date
CN105492007A (zh) 2016-04-13
KR20160003182A (ko) 2016-01-08
EP2991650A4 (en) 2017-01-25
HK1223547A1 (zh) 2017-08-04
JP6860949B2 (ja) 2021-04-21
EP2991650A1 (en) 2016-03-09
JP2019112416A (ja) 2019-07-11
WO2014179738A1 (en) 2014-11-06
JP2016522188A (ja) 2016-07-28

Similar Documents

Publication Publication Date Title
RU2745678C2 (ru) Способы лечения рака
Gucalp et al. Targeting the androgen receptor in triple-negative breast cancer
JP6195384B2 (ja) 乳癌の処置方法
JP6860949B2 (ja) 癌の処置方法
US20230061048A1 (en) Selection of patients for combination therapy
KR20180022926A (ko) 암 치료를 위한 hdac 억제제와 항-pd-l1 항체의 조합
US20230088701A1 (en) Combination therapies for treatment of breast cancer
TW202014190A (zh) 用於治療淋巴瘤之方法
US20220241294A1 (en) Bisfluoroalkyl-1,4-benzodiazepinone compounds for treating notch-activated breast cancer
US20130150386A1 (en) Methods for the treatment of lung cancer
JP2022514056A (ja) 癌の治療に使用するためのＲａｆ阻害剤及びＣＤＫ４／６阻害剤による組み合わせ療法

Legal Events

Date Code Title Description
AMND Amendment
AMND Amendment
E902 Notification of reason for refusal
AMND Amendment
E601 Decision to refuse application
AMND Amendment
X701 Decision to grant (after re-examination)
GRNT Written decision to grant